Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.112”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [112]
In the citing paper
“This issue can often be overcome using high-dose cyclophosphamide or the CXCR4 antagonist plerixafor125.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [125]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“dtd"[ ]> Introduction High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“11 Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma”
BackgroundRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citationThalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Self-citationBarlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0551 · Cited by 399
Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0522 · Cited by 369
Harousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 367
Dispenzieri, A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., et al. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61029-x · Cited by 223
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kyle, R. A. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.10.1371 · Cited by 209
Self-citationCavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., Vivo, A. D., Palareti, G., et al. (2004) · PubMed · Cited by 191
Desikan, K. R., Barlogie, B., Jagannath, S., Vesole, D. H., Siegel, D., Fassas, A., Munshi, N., Singhal, S., Mehta, J., Tindle, S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1547 · Cited by 156
Alegre, A. M., Tomás, J., Martínez‐Chamorro, C., Gil‐Fernández, J. J., Fernández-Villalta, M. J., Arranz, R., Díaz, M. Á., Granda, A., Bernardo, M. P., Escudero, A., et al. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700867 · Cited by 136
Goldschmidt, H., Hegenbart, U., Wallmeier, M., Hohaus, S., & Haas, R. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2783095.x · Cited by 107
Boccadoro, M., Palumbo, A., Bringhen, S., Merletti, F., Ciccone, G., Richiardi, L., Rus, C., Bertola, A., Giaccone, L., Omedè, P., et al. (2002) · PubMed · Cited by 83
Perea, G., Sureda, A. M., Martino, R., Altés, A., Martínez, C., Cabezudo, M.-E., Amill, B., n-Henao, G. M. X. E., lez, Y. G. X. E., Muñoz, L., et al. (2001) · Annals of Hematology · doi:10.1007/s002770100351 · Cited by 81 · cited 1×
“Previous studies have demonstrated reduced stem cell yields with other therapies as well when continued for more than 12 months from diagnosis before stem cell collection”
BackgroundQazilbash, M. H., Saliba, R. M., Lima, M. J. G. D., Hosing, C. M., Couriel, D. R., Aleman, A., Roden, L., Champlin, R. E., & Giralt, S. (2006) · Cancer · doi:10.1002/cncr.21700 · Cited by 76 · cited 1×
“This coupled with the demonstrated role of salvage stem cell transplant at relapse, especially for patients deriving a long progression free survival from the initial transplant has resulted in many institutions attempting to collect stem cells for up to three transplants”
BackgroundBreitkreutz, I., Lokhorst, H. M., Raab, M., van der Holt, B., Cremer, F. W., Herrmann, D., Glasmacher, A. G., Schmidt‐Wolf, I. G. H., Blau, I. W., Martin, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404661 · Cited by 75
The role of second autografts in the management of myeloma at first relapse.
Alvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., & Morgan, G. J. (2006) · PubMed · Cited by 74
de la Rubia, J., Bladé, J., Lahuerta, J.-J., Ribera, J., Martínez, R., Alegre, A. M., García‐Laraña, J., Fernández, P., Sureda, A. M., de Arriba, F., et al. (2006) · PubMed · Cited by 61
Bladé, J., Esteve, J., Rives, S., Martínez, C., Rovira, M., Urbano-Ispizúa, Á., Marín, P., Carreras, E., & Montserrat, E. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702622 · Cited by 53
Knudsen, L. M., Rasmussen, T., Jensen, L., & Johnsen, H. E. (1999) · Medical Oncology · doi:10.1007/bf02785870 · Cited by 42
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
Ghobrial, I. M., Dispenzieri, A. A., Bundy, K. L., Gastineau, D. A., Rajkumar, S. V., Therneau, T. M., Lacy, M. Q., Witzig, T. E., Litzow, M. R., Christensen, B. R., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704173 · Cited by 36
Self-citationCavo, M., Tacchetti, P., Zamagni, E., Tosi, P., Cangini, D., Cellini, C., Testoni, N., Vivo, A. D., Perrone, G., Tura, S., et al. (2004) · Blood · doi:10.1182/blood.v104.11.1489.1489 · Cited by 18
Impaired PBPC collection in patients with myeloma after high-dose melphalan
Jansen, J., Thompson, J. M., Dugan, M. J., Wiemann, M. C., Hanks, S., Greenspan, A., & Akard, L. P. (2004) · Cytotherapy · doi:10.1080/14653240410005023 · Cited by 13 · cited 1×
“7 These effects of melphalan have been related to the cumulative dose as well as the specific dosing schedule employed; however, no prospective trial has systematically examined the factors influencing the ability to collect stem cell after exposure to melphalan”
Background
Cited by
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.(96) Patients who have received more than 4–6 cycles of lenalidomide may need plerixafor for stem cell mobilization.”
MethodSelf-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.(94) Patients who have received more than 4-6 cycles of lenalidomide may need plerixafor for stem cell mobilization.”
MethodSelf-citationDiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N. M., Stiff, P. J., Kaufman, J. L., Maziarz, R. T., Hosing, C., Früehauf, S., Horwitz, M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174946 · Cited by 789
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., & Gertz, M. A.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Kumar, S
- ORCID
- Venue
- Leukemia
- Published
- 2007-06-21
- Volume
- 21
- Issue
- 9
- Pages
- 2035-2042
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2036985459
- Semantic Scholar
- 831eb40600d3fcbfc29f2b9cc655e7c78f420e1f
- Cited by
- 351
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 29 · 2012: 27
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- lenalidomide, peripheral blood stem cell mobilization, stem cell engraftment, multiple myeloma, newly diagnosed multiple myeloma, granulocyte colony-stimulating factor, CD34+ cell yield, apheresis, VAD chemotherapy, bortezomib, mobilization failure
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Vincristine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hormonal, Hematopoietic Stem Cell Mobilization, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.